Biologics Drug Discovery Market Overview
The Biologics Drug Discovery Market is experiencing steady expansion as pharmaceutical and biotechnology companies increase investments in biologics research, personalized medicine, and advanced drug discovery technologies. The market was valued at USD 36.9 billion in 2024 and is expected to reach USD 38.9 billion in 2025, growing to USD 65.0 billion by 2035 at a CAGR of 5.3% during the forecast period.
The market is being supported by increasing R&D investment, the growing prevalence of chronic diseases, advances in biotechnology, rising demand for personalized medicine, and an expanding biopharmaceutical pipeline. North America held the largest regional share, valued at USD 15.0 billion in 2024 and projected to reach USD 25.0 billion by 2035. Oncology is the leading application segment, with a market value of USD 15.0 billion in 2024 and an expected value of USD 25.0 billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=575084
Key Companies in the Biologics Drug Discovery Market
Novartis
Pfizer
Eli Lilly
BristolMyers Squibb
Roche
Takeda Pharmaceutical
Biogen
Merck & Co
Sanofi
Amgen
Johnson & Johnson
Regeneron Pharmaceuticals
Genentech
AbbVie
Gilead Sciences
The Biologics Drug Discovery Market is being driven by the rising prevalence of chronic diseases, increasing investment in biopharmaceutical research, and technological advancements in high-throughput screening, bioinformatics, genomic sequencing, protein engineering, and artificial intelligence. The growing focus on personalized medicine is also encouraging pharmaceutical companies to develop targeted biologic therapies designed around specific patient profiles.
The market is segmented by Application, Type, Technique, End Use, and Region. By Application, the market includes Oncology, Autoimmune Disorders, Cardiovascular Diseases, Infectious Diseases, and Neurological Disorders. By Type, it covers Monoclonal Antibodies, Vaccines, Recombinant Proteins, Gene Therapy, and Cell Therapy. By Technique, the market includes High-Throughput Screening, Genomic Sequencing, Bioassays, Protein Engineering, and CRISPR Technology. End users comprise Pharmaceutical Companies, Biotechnology Companies, Research Institutions, and Contract Research Organizations.
The market presents significant opportunities through the expansion of personalized medicine, increasing adoption of AI-driven drug discovery, growth in gene therapy approaches, and rising investments in biotechnology. Companies can also benefit from partnerships with biotechnology startups and expansion into emerging markets, particularly across Asia-Pacific, where biotechnology capabilities and healthcare investments are increasing.
Recent Developments and Market Trends:
Novartis announced a strategic partnership in March 2025 to accelerate biologics drug discovery using AI-enabled platforms.
Roche announced a major collaboration in June 2025 to accelerate the discovery of next-generation monoclonal antibodies.
Pfizer announced an acquisition in April 2024 aimed at strengthening its antibody discovery capabilities.
High-throughput screening and automated drug discovery technologies are increasingly improving the speed and efficiency of biologics development.
AI and machine learning are gaining importance in predictive modeling and biologics drug discovery workflows.
Growing collaboration between biotechnology companies, research institutions, and pharmaceutical companies is supporting innovation across the biologics pipeline.
Reasons to Buy the Report:
Understand the current size, growth trajectory, and long-term outlook of the global Biologics Drug Discovery Market.
Analyze key growth drivers including biotechnology advancements, R&D investment, chronic disease prevalence, and personalized medicine.
Evaluate market opportunities across applications, biologic types, discovery techniques, end users, and regional markets.
Assess the competitive landscape and strategies of leading pharmaceutical and biotechnology companies.
Identify the impact of AI, genomic sequencing, protein engineering, and other technologies on biologics drug discovery.
Gain insights into regional growth opportunities, particularly across North America, Europe, and Asia-Pacific.
Future Outlook:
The Biologics Drug Discovery Market is positioned for sustained growth through 2035, supported by expanding biopharmaceutical pipelines, technological innovation, increasing R&D expenditure, and the growing demand for targeted and personalized therapies. North America is expected to remain a leading regional market, while Asia-Pacific is positioned for significant expansion as biotechnology capabilities and healthcare investment increase. With the market projected to reach USD 65.0 billion by 2035 at a 5.3% CAGR, continued advances in AI, genomic technologies, high-throughput screening, gene therapy, and cell therapy are expected to shape the next phase of biologics drug discovery.
➤➤Explore Our Latest Related Reports:
